- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Urothelial cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1258KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 698KB)
Enfortumab vedotin – March 2022
Enfortumab vedotin: Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev®
Last updated
15 July 2022